NASDAQ
9.75USD
+0.25 (+2.64%)
We have scored 3 news catalysts on Puma Biotechnology, Inc. (PBYI) over the past 12 months. The biggest single-day move next to one of them came Nov 1, 2025, when PBYI closed −6.6%: “15,168 Shares in Puma Biotechnology, Inc. $PBYI Bought by Ethic Inc.”. Coverage across the window leans positive (average ticker sentiment +0.40). Most of the impact sits in downstream customer concentration and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
496.3M
P/E
—
EPS
—
Beta
1.21
52W range
4.58-10.1
Day range
9.45–9.80
Open
9.45
Prev close
9.50
Volume
53.9K
Avg volume
319.9K
Dividend
0.00
IPO
2012-04-24
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Puma Biotechnology, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for PBYI: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
